Amgen Boosts Bid for Onyx to $130 a Share

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Ray Dalio's Honest 'Radical Transparency' Approach
28:40 - Mark Lehmann, president at JMP Securities, and Bloomberg's Christine Harper talk about the culture at Bridgewater Associates, Chairman Ray Dalio's idea of "radical transparency" and his feud with heir apparent Greg Jensen. They speak on "Bloomberg ‹GO›." (Source: Bloomberg)
  • Deutsche Bank's Checklist to Regain Investor Trust
  • Weak Ratings Pressure Ad Sales at Viacom
  • Japanese Banks Sink as 10-Year Bond Goes Negative